RxDoctor Payments Data

Tyler Moore, MD

Ophthalmology · Fort Worth, TXNPI 1215375928

Payments from drug & device makers

$2,727in general payments, 2019–2025

Across 49 payments — averaging $55.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$2K
  • Bausch & Lomb Americas Inc.$160
  • Sun Pharmaceutical Industries Inc.$130
  • AbbVie$126
  • Genmab U.S., Inc.$125
  • Kala Pharmaceuticals, Inc.$119
  • plus $403 from 15 others

What the payments were for

  • Speaking & faculty fees$1,50055%
  • Food & beverage$1,16343%
  • Gifts$642%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,727 in reported general payments places this provider in the 55th percentile of 1,355 ophthalmology providers in Texas.

See all ophthalmology providers in Texas

Medicare billing

Part B allowed, 2024
$280,989
Medicare patients
911
Services billed
2,727

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine53$71,477
LumiganBimatoprost86$48,285
Cyclosporine25$22,658
CombiganBrimonidine Tartrate/Timolol35$18,263
VyzultaLatanoprostene Bunod25$13,392
Prednisolone Acetate286$11,212
Alphagan PBrimonidine Tartrate19$9,954
Travoprost45$8,394
ProlensaBromfenac Sodium24$8,220
RocklatanNetarsudil Mesylat/Latanoprost11$6,483
Latanoprost640$6,483
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol37$5,838
MoxifloxacinMoxifloxacin Hcl254$5,539
SimbrinzaBrinzolamide/Brimonidine Tart21$5,527
Difluprednate45$4,345

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan, Alphagan P$126$147,979193 claims
Bausch & Lomb Americas Inc.Vyzulta$160$13,39225 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa$30$8,22024 claims
Aerie Pharmaceuticals, Inc.Rocklatan$16$6,48311 claims
AlconSimbrinza$75$5,52721 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,355 ophthalmology providers in Texas.

Other ophthalmology in Fort Worth

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →